Despite the tough public financing environment, venture capitalists are more than willing to dole out the dollars to support good ideas, good science and good management. (BioWorld Financial Watch)
Private biotech companies planning to go public played the waiting game in 2001. They waited for the right moment, when the window would fly up and investors would flock to their brokers. But just as that window started to inch open late last year, it immediately slammed shut again upon news of accounting scandals and clinical blowups. (BioWorld Financial Watch)
